You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethantheline
Accession NumberDB00940  (APRD00751)
TypeSmall Molecule
GroupsApproved
DescriptionMethantheline is a synthetic antispasmodic. Antispasmodics are used to relieve cramps or spasms of the stomach, intestines, and bladder. Methantheline is used to treat intestine or stomach ulcers (peptic ulcer disease), intestine problems (irritable bowel syndrome), pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, or urinary problems (reflex neurogenic bladder in children).
Structure
Thumb
Synonyms
Methantheline
Methanthelinium
Methanthelinum
External Identifiers
  • MTB 51
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BanthineNot Available
VagantinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methantheline Bromide
Thumb
  • InChI Key: PQMWYJDJHJQZDE-UHFFFAOYSA-M
  • Monoisotopic Mass: 419.10960635
  • Average Mass: 420.34
DBSALT000228
Categories
UNII36EI79TX7I
CAS number5818-17-7
WeightAverage: 340.436
Monoisotopic: 340.191268703
Chemical FormulaC21H26NO3
InChI KeyInChIKey=GZHFODJQISUKAY-UHFFFAOYSA-N
InChI
InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1
IUPAC Name
diethyl(methyl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
SMILES
CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as xanthenes. These are polycyclic aromatic compounds containing a xanthene moiety, which consists of two benzene rings joined to each other by a pyran ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzopyrans
Sub Class1-benzopyrans
Direct ParentXanthenes
Alternative Parents
Substituents
  • Xanthene
  • Diaryl ether
  • Acyl choline
  • Choline
  • Benzenoid
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Oxacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children.
PharmacodynamicsMethantheline is a synthetic quarternary ammonium antimuscarinic used to relieve cramps or spasms of the stomach, intestines, and bladder. It can be used together with antacids or other medicines, such as H2-receptor antagonists, in the treatment of peptic ulcer. Methantheline inhibits muscarinic actions at postganglionic parasympathetic neuroeffector sites.
Mechanism of actionMethantheline inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands. Depending on the dose, anticholinergics may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder.
Related Articles
AbsorptionRapidly absorbed.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic, by enzymatic hydrolysis.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose: blurred vision (continuing) or changes in near vision, clumsiness or unsteadiness, confusion, convulsions, difficulty in breathing, muscle weakness (severe), or tiredness (severe), dizziness, drowsiness (severe), dryness of mouth, nose, or throat (severe), fast heartbeat, fever, hallucinations, slurred speech, unusual excitement, nervousness, restlessness, or irritability, unusual warmth, dryness, and flushing of skin.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9075
Blood Brain Barrier+0.9411
Caco-2 permeable+0.648
P-glycoprotein substrateSubstrate0.8327
P-glycoprotein inhibitor INon-inhibitor0.817
P-glycoprotein inhibitor IINon-inhibitor0.5977
Renal organic cation transporterNon-inhibitor0.5359
CYP450 2C9 substrateNon-substrate0.8214
CYP450 2D6 substrateNon-substrate0.599
CYP450 3A4 substrateSubstrate0.6801
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8476
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5637
Ames testNon AMES toxic0.8371
CarcinogenicityNon-carcinogens0.7407
BiodegradationNot ready biodegradable0.5863
Rat acute toxicity2.7675 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7426
hERG inhibition (predictor II)Inhibitor0.7318
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000132 mg/mLALOGPS
logP0.5ALOGPS
logP-0.47ChemAxon
logS-6.5ALOGPS
pKa (Strongest Acidic)18.1ChemAxon
pKa (Strongest Basic)-7.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity110.42 m3·mol-1ChemAxon
Polarizability37.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA03AB07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Methantheline can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumAclidinium may increase the anticholinergic activities of Methantheline.
AclidiniumThe risk or severity of adverse effects can be increased when Methantheline is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Methantheline is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methantheline is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Methantheline can be decreased when used in combination with Ambenonium.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Methantheline.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Methantheline.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methantheline.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Methantheline.
BenactyzineThe risk or severity of adverse effects can be increased when Methantheline is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Methantheline.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Methantheline.
BezitramideThe risk or severity of adverse effects can be increased when Methantheline is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Methantheline.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Methantheline.
Botulinum Toxin Type AMethantheline may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BMethantheline may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Methantheline is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Methantheline is combined with Butorphanol.
CarfentanilThe risk or severity of adverse effects can be increased when Methantheline is combined with Carfentanil.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Methantheline.
CefpodoximeMethantheline can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CefuroximeMethantheline can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Methantheline.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Methantheline is combined with Chlorphenoxamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Methantheline.
CimetropiumMethantheline may increase the anticholinergic activities of Cimetropium.
CodeineThe risk or severity of adverse effects can be increased when Methantheline is combined with Codeine.
CoumaphosThe therapeutic efficacy of Methantheline can be decreased when used in combination with Coumaphos.
CyclopentolateThe risk or severity of adverse effects can be increased when Methantheline is combined with Cyclopentolate.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Methantheline.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Methantheline.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Methantheline.
DasatinibMethantheline can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DecamethoniumThe therapeutic efficacy of Methantheline can be decreased when used in combination with Decamethonium.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Methantheline.
DemecariumThe therapeutic efficacy of Methantheline can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Methantheline is combined with Desloratadine.
DexetimideThe risk or severity of adverse effects can be increased when Methantheline is combined with Dexetimide.
DexmethylphenidateMethantheline can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextromoramideThe risk or severity of adverse effects can be increased when Methantheline is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methantheline is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Methantheline can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methantheline.
DihydrocodeineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Methantheline is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Methantheline can be decreased when used in combination with Donepezil.
DPDPEThe risk or severity of adverse effects can be increased when Methantheline is combined with DPDPE.
DronabinolMethantheline may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Methantheline can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Methantheline can be decreased when used in combination with Edrophonium.
EluxadolineMethantheline may increase the constipating activities of Eluxadoline.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Methantheline.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Methantheline.
EthylmorphineThe risk or severity of adverse effects can be increased when Methantheline is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Methantheline is combined with Etorphine.
FentanylThe risk or severity of adverse effects can be increased when Methantheline is combined with Fentanyl.
FenthionThe therapeutic efficacy of Methantheline can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Methantheline is combined with Fesoterodine.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Methantheline.
GalantamineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Methantheline.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Methantheline.
Ginkgo bilobaThe therapeutic efficacy of Methantheline can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Methantheline is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Methantheline.
GlycopyrroniumMethantheline may increase the anticholinergic activities of Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Methantheline is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Methantheline is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Methantheline is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Methantheline can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methantheline.
HydrocodoneThe risk or severity of adverse effects can be increased when Methantheline is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Methantheline.
HydromorphoneThe risk or severity of adverse effects can be increased when Methantheline is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methantheline.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Methantheline.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Methantheline.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methantheline.
IsoflurophateThe therapeutic efficacy of Methantheline can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Methantheline.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Methantheline.
KetobemidoneThe risk or severity of adverse effects can be increased when Methantheline is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Methantheline.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Methantheline.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methantheline is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Methantheline is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Methantheline is combined with Lofentanil.
MalathionThe therapeutic efficacy of Methantheline can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methantheline.
MefloquineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Memantine.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Methantheline.
MethadoneThe risk or severity of adverse effects can be increased when Methantheline is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methantheline is combined with Methadyl Acetate.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Methantheline.
MethylphenidateMethantheline can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MetixeneThe risk or severity of adverse effects can be increased when Methantheline is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Methantheline.
MianserinMianserin may increase the anticholinergic activities of Methantheline.
MinaprineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Methantheline is combined with Mirabegron.
MorphineThe risk or severity of adverse effects can be increased when Methantheline is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Methantheline is combined with N-butylscopolammonium bromide.
NabiloneMethantheline may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Methantheline is combined with Nalbuphine.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Methantheline.
NeostigmineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Neostigmine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Methantheline.
NormethadoneThe risk or severity of adverse effects can be increased when Methantheline is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Methantheline is combined with NVA237.
OpiumThe risk or severity of adverse effects can be increased when Methantheline is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Methantheline is combined with Orphenadrine.
OxybutyninThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Methantheline.
PancuroniumThe risk or severity of adverse effects can be increased when Methantheline is combined with Pancuronium.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Methantheline.
PentazocineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Methantheline is combined with Pentolinium.
PethidineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pethidine.
PhysostigmineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Physostigmine.
PipecuroniumThe risk or severity of adverse effects can be increased when Methantheline is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Methantheline.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Methantheline.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Methantheline.
Potassium ChlorideMethantheline may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Methantheline.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methantheline.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Methantheline.
PyridostigmineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Methantheline.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Methantheline.
RamosetronMethantheline may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Methantheline is combined with Remifentanil.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Methantheline.
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Methantheline.
RivastigmineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Rivastigmine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Methantheline.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methantheline.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Methantheline is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Methantheline.
SolifenacinThe risk or severity of adverse effects can be increased when Methantheline is combined with Solifenacin.
SufentanilThe risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Methantheline.
TacrineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Methantheline is combined with Tapentadol.
TiotropiumMethantheline may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Methantheline.
TolterodineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Methantheline is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Methantheline is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Methantheline can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Methantheline.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methantheline.
TrimethaphanThe risk or severity of adverse effects can be increased when Methantheline is combined with Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Methantheline.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Methantheline.
TubocurarineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Methantheline.
UmeclidiniumThe risk or severity of adverse effects can be increased when Methantheline is combined with Umeclidinium.
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Methantheline.
VecuroniumThe risk or severity of adverse effects can be increased when Methantheline is combined with Vecuronium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Hough LB, Barker LA: Histamine H2-receptor antagonism by propantheline and derivatives. J Pharmacol Exp Ther. 1981 Nov;219(2):453-8. [PubMed:6116801 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23